Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.36 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27885042 | 0.80 | KDM1A (0.38) | OPRM1OPRL1HTR1ASLC6A2SLC6A3 | |
| SCHEMBL10812665 | 0.80 | KDM1A (0.38) | OPRM1OPRL1HTR1ASLC6A2SLC6A3 | |
| SCHEMBL9000261 | 0.79 | DPP4 (0.36) | HTR1AICMTDPP4TSHR | |
| SCHEMBL14720863 | 0.78 | SLC6A3 (0.51) | OPRM1OPRL1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL434816 | 0.76 | HSD11B1 (0.38) | OPRM1OPRL1DPP4 | |
| SCHEMBL31343992 | 0.76 | OPRM1 (0.34) | OPRM1OPRL1DPP4SLC6A4SLC6A2 | |
| SCHEMBL7147295 | 0.76 | HTR2A (0.39) | HTR1ASLC6A4SLC6A2SLC6A3MMP2 | |
| SCHEMBL14778102 | 0.75 | TSHR (0.40) | OPRM1OPRL1TSHR | |
| SCHEMBL14779453 | 0.75 | TSHR (0.40) | OPRM1OPRL1TSHR | |
| SCHEMBL22530353 | 0.75 | DPP4 (0.33) | HTR1AICMTDPP4SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103140209-B | Oral care composition with improved local flavor | 宝洁公司 | 2017-10-13 | — | — | CN | claimed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | claimed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | claimed |
| EP-3360175-B1 | FORMULATIONS COMPRISING AT LEAST TWO ORGANIC SEMICONDUCTING COMPOUNDS AND AT LEAST TWO SOLVENTS | MERCK PATENT GMBH (DE) | 2023-05-17 | — | — | EP | disclosed |
| US-10686132-B2 | Formulations comprising organic at least two semiconducting compounds and at least two solvents | MERCK PATENT GMBH (DE) | 2020-06-16 | — | — | US | disclosed |
| EP-2621462-B1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | PROCTER & GAMBLE (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190115536-A1 | FORMULATIONS COMPRISING ORGANIC AT LEAST TWO SEMICONDUCTING COMPOUNDS AND AT LEAST TWO SOLVENTS | MERCK PATENT GMBH (DE) | 2019-04-18 | — | — | US | disclosed |
| US-9937115-B2 | Oral care compositions with improved flavor | THE PROCTER & GAMBLE COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| CN-103140209-B | Oral care composition with improved local flavor | 宝洁公司 | 2017-10-13 | — | — | CN | disclosed |
| EP-2621462-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | The Procter and Gamble Company (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044728-A1 | ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR | THE PROCTER & GAMBLE COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | THE PROCTER & GAMBLE COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082628-A1 | Oral Care Compositions With Improved Flavor | TRPA1, TAS2R40, TAS2R30 | OPRM1 202/4885OPRL1 418/4885HTR1A 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.